Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma. - Yao Y; Yan Y; Suman VJ; Dietz AB; Erskine CL; Dimou A; Markovic SN; McWilliams RR; Montane HN; Block MS (Frontiers in immunology, 2025)